Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks.

TheFly reported on May 28 that Morgan Stanley upgraded HCM to Equal Weight from Underweight and set a new price target of $13.60, slightly below the prior $13.75 level. The firm noted that China biotech valuations have reset to more attractive entry levels, improving the sector’s risk-reward profile. It also pointed to FY26 guidance that continues to suggest solid growth in innovator revenue, alongside ongoing strength in outbound licensing activity.

On May 21, HUTCHMED (China) Limited (NASDAQ:HCM) and Innovent Biologics announced that China’s National Medical Products Administration (NMPA) approved their New Drug Application for the combination therapy of Elunate and Tyvyt. The approval covers the treatment of patients with locally advanced or metastatic renal cell carcinoma who have previously been treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors and have not received PD-1 or PD-L1 inhibitor therapy in the first-line setting.

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

This regulatory decision expands the clinical use of the combination regimen in a more defined patient population with prior treatment exposure. The update marks an important step in advancing the availability of the dual therapy option within China’s oncology treatment landscape.

HUTCHMED (China) Limited (NASDAQ:HCM) is a biopharmaceutical company focused on developing targeted cancer therapies and immunotherapies. Founded in 2000 and based in Hong Kong, it has a fully integrated R&D platform supported by around 900 scientists.

While we acknowledge the risk and potential of HCM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HCM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1